Recruiting

Surgical Treatment

Sponsor:

Population Health Research Institute

Code:

NCT04743765

Conditions

Hip Fractures

Myocardial Injury

Eligibility Criteria

Sex: All

Age: 45+

Healthy Volunteers: Not accepted

Interventions

Accelerated medical clearance and surgery

Study Details

Brief summary:

The HIP ATTACK-2 trial is a multicentre, international, parallel group randomized controlled trial to determine whether accelerated surgery for hip fracture in patients with acute myocardial injury is superior to standard care in reducing death at 90 days after randomization. The trial will also assess secondary outcomes at 90 days after randomization: inability to independently walk 3 metres, time to first mobilization (first standing and first full weight bear), composite and individual assessment of major complications (e.g., mortality, non-fatal myocardial infarction, acute congestive heart failure, and stroke), delirium, length of stay, pain, and quality of life.

Conditions

Hip Fractures

Myocardial Injury

Study ID

NCT04743765

Start date

Nov 22, 2021

Status verified date

Sep, 2025

Completion date

Nov 30, 2027

Anticipated

Primary completion date

Aug 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 45+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. age ≥45 years;
2. diagnosis of hip fracture during working hours with a low-energy mechanism requiring surgery;
3. troponin elevation ( at least one troponin measurement above the upper limit of normal occurring from the time of hip fracture to the time of randomization); and
4. informed consent.

Exclusion Criteria:

1. taking a therapeutic dose of an anticoagulant for which no reversing agent is available and the anesthesiologist or surgeon believe surgery within 6 hours of eligibility criteria met would not be safe;
2. patients on a therapeutic vitamin K antagonist with a history of heparin induced thrombocytopenia (HIT);
3. patients with peri-prosthetic fracture, open fracture or bilateral fractures;
4. patients requiring an emergency surgery for another reason (e.g., subdural hematoma);
5. patients with acute myocardial infarction deemed to be clinically unstable, with a mechanical complication (i.e., acute papillary muscle rupture, ventricular septal defect), ST elevation myocardial infarction, or cardiogenic shock;
6. patients refusing consent; or
7. patients previously enrolled in HIP ATTACK-2.

Study Design

Enrollment

1100 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Accelerated medical clearance and surgery

Accelerated medical clearance and targeted arrival to the operating room within 6 hours of eligibility criteria met.

no intervention: Standard surgical care

Hip fracture repair and surgical care according to treating institution guidelines.

Interventions

Accelerated medical clearance and surgery

Rapid medical clearance with targeted arrival to the operating room within 6 hours of eligibility criteria criteria met.

Primary outcome measure

  • All cause mortality [ Time Frame: Within 90 days post randomization ]

Central Contacts and Locations

Central contacts

Locations

St. Joseph's Healthcare Hamilton

Recruiting

Hamilton, Ontario, Canada, L8N 4A6

Contacts

Principal Investigator:

Flavia Borges, MD

Juravinski Hospital

Recruiting

Hamilton, Ontario, Canada, L8V 1C3

Contacts

Principal Investigator:

Ameen Patel, MD

Victoria Hospital

Recruiting

London, Ontario, Canada, N6A 5W9

Contacts

Principal Investigator:

Abdel Lawendy, MD

Markham Stouffville Hospital

Recruiting

Markham, Ontario, Canada, L3P 7P3

Contacts

Principal Investigator:

Steve McMahon, MD

Ottawa General Hospital

Recruiting

Ottawa, Ontario, Canada, K1H 8L6

Contacts

Principal Investigator:

Robert Feibel, MD

CISSS de Laval

Recruiting

Laval, Quebec, Canada, H7M 3L9

Contacts

Principal Investigator:

Maxime Beaumont-Courteau, MD

More Information

Sponsor

Population Health Research Institute

Last update posted

Aug 26, 2026

Last verified

Sep, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Population Health Research Institute on 2026-08-26.